HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Rani Therapeutics Holdings, maintaining a price target of $9.
October 18, 2024 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Rani Therapeutics Holdings, maintaining a price target of $9.
The reiteration of a Buy rating and maintenance of a $9 price target by HC Wainwright & Co. is a positive signal for investors, suggesting confidence in Rani Therapeutics Holdings' future performance. This could lead to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100